Dey Sarkar Rupak, Sinha Samraj, Biswas Nabendu
Department of Life Sciences, Presidency University, Kolkata, India.
Int Rev Immunol. 2021;40(3):171-182. doi: 10.1080/08830185.2021.1876044. Epub 2021 Jan 29.
Chronic inflammation has emerged as a key player at different stages of cancer development. A prominent signaling pathway for acute and chronic inflammation is the activation of the caspase-1 inflammasomes. These are complexes that assemble on activation of certain nucleotide-binding domain, leucine-rich repeat containing proteins (NLRs), AIM2-like receptors (ALRs), or pyrin due to activation via PAMPs or DAMPs. Of these, five complexes-NLRP1, NLRP3, NLRC4, Pyrin, and AIM2 are of importance in the context of cancer for their activities in modulating immune responses, cell proliferation, and apoptosis. Inflammasomes have emerged as clinically relevant in multiple forms of cancer making them highly promising targets for cancer therapy. As lungs are a tissue niche that is prone to inflammation owing to its exposure to external substances, inflammasomes play a vital role in the development and pathogenesis of lung cancer. Therefore, manipulation of inflammasome by various immunomodulatory means could prove a full-proof strategy for the treatment of lung cancer. Here, in this review, we tried to explore the various strategies to target the inflammasomes for the treatment of lung cancer.
慢性炎症已成为癌症发展不同阶段的关键因素。急性和慢性炎症的一个重要信号通路是半胱天冬酶-1炎性小体的激活。这些是在某些核苷酸结合结构域、富含亮氨酸重复序列的蛋白质(NLRs)、AIM2样受体(ALRs)或由于通过病原体相关分子模式(PAMPs)或损伤相关分子模式(DAMPs)激活而形成的吡啉激活时组装的复合物。其中,五种复合物——NLRP1、NLRP3、NLRC4、吡啉和AIM2在癌症背景下因其在调节免疫反应、细胞增殖和凋亡方面的活性而具有重要意义。炎性小体在多种癌症形式中已显示出与临床相关,使其成为极具前景的癌症治疗靶点。由于肺是一个因暴露于外部物质而易于发生炎症的组织微环境,炎性小体在肺癌的发展和发病机制中起着至关重要的作用。因此,通过各种免疫调节手段操纵炎性小体可能是治疗肺癌的一种万无一失的策略。在此综述中,我们试图探索针对炎性小体治疗肺癌的各种策略。